Lpath to Hold Corporate Update Conference Call and Live Webcast on Tuesday, November 17th
Company to Present Additional Data From the Nexus Phase 2 Study of iSONEP™
SAN DIEGO, Nov. 16, 2015 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today that the company will host a conference call and live webcast tomorrow, Tuesday, November 17, 2015 beginning at 5:00 p.m. EST/2:00 p.m. PST to provide a corporate update and review data from the Nexus Phase 2 study that evaluated iSONEP™ as a treatment for patients with wet age-related macular degeneration. The data from the Nexus study was recently presented at the American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day.
To participate in the live call, please dial 1-855-239-3117 (domestic) or 1-412-542-4126 (international) or 1-855-669-9657 (Canada) and ask to join the Lpath conference call. A live webcast of the call and accompanying slides can be accessed on the "Investor Center: Calendar of Events" section of Lpath's corporate website at www.Lpath.com. A webcast replay will be available shortly after the call at the same web address.
About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN) is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease. The company has developed four drug candidates, has advanced the first two to mid-stage trials and built evidence to support its approach of targeting bioactive lipids to treat a wide range of diseases. For more information, visit www.lpath.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include but are not limited to, statements regarding the Company's development plans, potential therapeutic uses for its drug candidates, and the timing for the Company to commence clinical trials of its drug candidates. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the final results of the Company's preclinical studies and clinical trials may be different from the Company's studies or interim data results and may not support further clinical development and/or the commercialization of its drug candidates; the Company may not successfully complete its existing and any additional clinical trials for its drug candidates on a timely basis, or at all; the Company may fail to obtain required governmental approvals for any of its drug candidates; and the Company may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K filed with the SEC on March 24, 2015 and its Quarterly Report on Form 10-Q filed with the SEC on Aug 11, 2015. Such documents may be read free of charge on theSEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
CONTACTS:
Gary Atkinson
Chief Executive Officer
Lpath, Inc.
858-926-3202
[email protected]
David Rozul
Canale Communications
619-849-5389
[email protected]
SOURCE Lpath, Inc.
Share this article